#USA #Orlando #Nordic Pharma #Lacrifill Gel #Dry Eye Treatment

Nordic Pharma to Showcase Lacrifill Canalicular Gel at AAO 2025

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is set to present new patient data and experiences concerning their innovative Lacrifill Canalicular Gel, a novel therapy aimed at alleviating symptoms of dry eye, during the American Academy of Ophthalmology (AAO) Annual Meeting from October 18 to 20, 2025, in Orlando, Florida. This gathering is a key event for ophthalmology professionals to learn about the latest advancements that can enhance patient care.

Dr. Jai Parekh, the Chief Commercial Officer of Eye Care U.S., stated, “Experts in ophthalmology attend the AAO to learn about innovations that benefit patients. We are excited to share that a remarkable 98.11% of patients surveyed, who used Lacrifill Canalicular Gel either for the first time or repetitively, expressed their willingness to use Lacrifill again in the future.” This statistic represents strong endorsement from the patient community regarding the effectiveness of Lacrifill.

To further highlight their dedication to ophthalmic health, Nordic Pharma has invited several prominent figures in the field to co-author an article for the upcoming issue of Expert Review of Ophthalmology. This piece will discuss considerations around canalicular occlusion in relation to cataract and refractive surgery, shedding light on how dry eye syndrome can impact surgery outcomes, recovery, and patient satisfaction.

Main author Dr. Vance Thompson points out, “The dry eye syndrome can significantly alter preoperative planning and postoperative recovery for patients undergoing cataract or refractive surgery. Lacrifill fills a niche as it is indicated for use over a period of up to six months, which allows for optimization of eye surface conditions preoperatively and maintenance of benefits post-surgery.”

As part of its commitment to advancing the field and supporting women in ophthalmology, Nordic Pharma is proud to sponsor the Women in Ophthalmology (WIO) awards and networking event, scheduled for Saturday, October 18, at 5:30 p.m. Dr. Lisa M. Nijm, Director at WIO, expressed gratitude for Nordic Pharma’s ongoing contribution to honoring notable women in ophthalmology and improving the professional landscape for female eye care providers.

Conference attendees are encouraged to visit Booth #1401, where they can participate in injection demonstrations and place orders for Lacrifill Canalicular Gel. The meeting will also feature insights from the TFOS Dry Eye Workshop (DEWS) III Report, published by the Tear Film Ocular Surface Society (TFOS), noting two studies on Nordic Pharma's novel cross-linked hyaluronic acid (HA) canalicular filler.

One study observed significant improvements in corneal staining and Schirmer test values three months post-administration. A second study compared Lacrifill Canalicular Gel against a standard hydrogel canal plug, confirming that the novel HA filler was both safe and well-tolerated, demonstrating statistically significant improvements in dry eye symptoms over six months.

For more information and ordering options for Lacrifill Canalicular Gel, please visit lacrifill.com.

About Nordic Group B.V.

Nordic Group B.V. is a mid-sized, privately held international pharmaceutical company focused on developing and marketing specialized products. Its portfolio expansion has been achieved through targeted development and strategic acquisitions in fields such as ophthalmology, rheumatology, and women’s health. The company has strong roots in Europe and has recently expanded its reach globally through increased acquisitions.

About Nordic Pharma, Inc.

Nordic Pharma, Inc. collaborates with renowned global biopharmaceutical companies, uniquely positioned to leverage expertise in the launch of biotechnologically produced medicines, sterile manufacturing processes, and other advanced technologies.

Forward-Looking Statements

This press release may contain forward-looking statements regarding the business development of Nordic Group/Nordic Pharma and the implementation of its strategic initiatives. These statements reflect the current views and expectations of the Nordic Group regarding future events, inherently involving risks and uncertainties that could cause actual outcomes and results to differ significantly from expectations. Factors include general market conditions, regulatory developments, and third-party financial conditions impacting Nordic Group/Nordic Pharma's business operations. The company does not undertake any obligation to publicly update forward-looking statements for any reason.

Contact Information

Nordic Pharma, Inc.
Kate Popova
Project and Contract Manager
Phone: 610-285-1699
Email: [email protected]

Gail Feerrar
Director of Sales and Marketing
Phone: 610-285-7152
Email: [email protected]